Name: Galectin Therapeutics Inc. (GALT) Cash Flow Statement
Creator: FinSpry

Galectin Therapeutics Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scale:

Scroll to see more

Cash flow statement showing operating, investing, and financing activities for Galectin Therapeutics Inc. (GALT) - Annual data in millions USD
Breakdown	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018
Operating Activities
Net Income	-47.05	-41.07	-38.78	-30.53	-23.47	-13.29	-13.90
Depreciation & Amortization	0.04	0.03	0.03	0.04	0.04	0.04	0.00
Stock Based Compensation	2.45	2.26	2.87	2.08	1.80	0.00	0.00
Change in Working Capital	2.28	4.68	4.97	3.96	0.94	0.73	-1.07
Change in Accounts Payable	-2.07	2.67	4.24	3.69	2.54	0.00	0.00
Change in Other Working Capital	4.36	2.01	0.72	0.27	-1.59	0.00	0.00
Other Operating Activities	0.51	3.39	-0.15	0.15	0.09	1.68	0.35
Net Cash from Operating Activities	-41.77	-32.97	-31.06	-24.31	-20.60	-10.85	-10.18
Investing Activities
Net Cash from Investing Activities	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financing Activities
Debt Repayment	30.00	0.00	0.00	0.00	0.00	0.00	0.00
Common Stock Issued	1.23	10.03	0.00	6.81	0.26	50.47	15.38
Dividends Paid	-0.09	0.00	0.00	0.00	0.00	0.39	0.00
Other Financing Activities	0.09	0.00	0.00	0.00	0.00	0.00	0.00
Net Cash from Financing Activities	31.23	40.03	10.00	36.81	0.26	50.08	15.38
Summary
Net Change in Cash	-10.54	7.07	-21.06	12.51	-20.34	39.23	5.20
Cash at Beginning of Period	25.66	18.59	39.65	27.14	0.00	8.25	3.05
Cash at End of Period	15.12	25.66	18.59	39.65	0.00	47.48	8.25
Free Cash Flow	-41.77	-32.97	-31.06	-24.31	0.00	-10.85	-10.18